FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2021/06/033918 [Registered on: 01/06/2021] Trial Registered Prospectively
Last Modified On: 28/05/2021
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Probiotic 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Efficacy of Bacillus Clausii in Acute Diarrhoea in Children 
Scientific Title of Study   An Open Labelled Study on Clinical Efficacy of Bacillus Clausii in Management of Acute Diarrhoea in Children 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Ramanath A 
Designation  Professor and Head of the Department 
Affiliation  Panimalar Medical College Hospital and Research Institute, 
Address  Department of Pediatrics Panimalar Medical College and Hospital Research Institute Varadharajapuram Poonamallee,

Chennai
TAMIL NADU
600123
India 
Phone  9884750160  
Fax    
Email  chandra.ramanath82@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Ramanath A 
Designation  Professor and Head of the Department 
Affiliation  Panimalar Medical College Hospital and Research Institute, 
Address  Department of Pediatrics Panimalar Medical College and Hospital Research Institute Varadharajapuram Poonamallee,

Chennai
TAMIL NADU
600123
India 
Phone  9884750160  
Fax    
Email  chandra.ramanath82@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Ramanath A 
Designation  Professor and Head of the Department 
Affiliation  Panimalar Medical College Hospital and Research Institute, 
Address  Department of Pediatrics Panimalar Medical College and Hospital Research Institute Varadharajapuram Poonamallee,

Chennai
TAMIL NADU
600123
India 
Phone  9884750160  
Fax    
Email  chandra.ramanath82@gmail.com  
 
Source of Monetary or Material Support  
Tablets India Limited 72 Marshalls Road Egmore Chennai 600008 
 
Primary Sponsor  
Name  Tablets India Limited 
Address  Jhaver center 72 Marshalls Road Egmore Chennai 600008 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Ramanath A  Panimalar Medical College Hospital and Research Institute  Department of Pediatrics Varadharajapuram Poonamallee Chennai 600123
Chennai
TAMIL NADU 
9884750160

chandra.ramanath82@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Panimalar Medical College Hospital and Research Institute - Institutional Human Ethics Committee (PMCHRI-IHEC)  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: K928||Other specified diseases of the digestive system,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Bacillus Clausii 2 billion CFU  Bacillus clausii 2 billion probiotic for kids – Maintains the right kind of gut flora balance Restores internal bacterial balance to help improve immunity Provides gentle gut care for your child Helps in restoring the natural balance of gut bacteria Addresses the root cause of digestive troubles such as diarrhoea and the like and promotes faster return of bacterial balance in the gut. Contributes to correct dysvitaminosis- which is the imbalance of production and assimilation of vitamins Works as effective diarrhoea management Dose Bacillus Clausii 2 billion CFU, two times a day, Route of administration per oral and duration five days 
Comparator Agent  Oral Rehydration Syrup (ORS) for children  The ORS for children works by neutralizing excess acid in the blood and urine Has been indicated for the treatment of metabolic acidosis Helps to restore lost electrolytes and fluids in the body Aids in the treatment dehydration caused by diarrhea, vomiting Dose Oral Rehydration Syrup two times a day, Route of administration per oral Duration of therapy five days 
 
Inclusion Criteria  
Age From  6.00 Month(s)
Age To  10.00 Year(s)
Gender  Both 
Details  Children aged between 6 months and 10 years with acute bacterial gastroenteritis or acute viral gastroenteritis.

Acute diarrhea for a duration of <3 days.
 
 
ExclusionCriteria 
Details  Severe dehydration and electrolyte imbalance
Presence of systemic infections
Children with known immunocomprising morbidities
Children with chronic or severe respiratory, cardiovascular, central nervous system, endocrine and other gastrointestinal disorders on clinical examination.
 
 
Method of Generating Random Sequence   Stratified block randomization 
Method of Concealment   An Open list of random numbers 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1.No. of stools per day after 24 hours of treatment
2.No. of stools per day after 48 hours of treatment
3.Duration of diarrhoea in days
 
1.No. of stools per day after 24 hours of treatment
2.No. of stools per day after 48 hours of treatment
3.Duration of diarrhoea in days
 
 
Secondary Outcome  
Outcome  TimePoints 
1.No. of episodes of vomiting
2.Changes in Stool consistency from 24 hrs to 48 hrs.
3.Body weight at baseline and day 5.
 
24 hrs to 48 hrs and Day 5 
 
Target Sample Size   Total Sample Size="50"
Sample Size from India="50" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 4 
Date of First Enrollment (India)   03/06/2021 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   Nil 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form
    Response -  Analytic Code

  3. Who will be able to view these files?
    Response - Anyone

  4. For what types of analyses will this data be available?
    Response - Any purpose.

  5. By what mechanism will data be made available?
    Response (Others) - 

  6. For how long will this data be available start date provided 21-05-2021 and end date provided 21-10-2025?
    Response - Immediately following publication. No end date.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - None
Brief Summary  

Acute gastroenteritis is an infectious syndrome that represents the first cause of hospitalization in children1.Diarrhea is usually a symptom of an infection in the intestinal tract, which can be caused by a variety of bacterial, viral and parasitic organisms. Infection is spread through contaminated food or drinking water, or from person-to-person as a result of poor hygiene2. Diarrhea due to infection is widespread throughout developing countries. In developing countries, children under 5 years of age experience on average three episodes of diarrhea every year3.One out of every five children who die of diarrhea worldwide is an Indian. Repeated episodes of diarrhea in children can result in long-term deleterious effects on nutritional status, possibly due to intestinal damage. Each episode deprives the child from the basic nutrition necessary for growth. As a result, diarrhea is a major cause ofmalnutrition, and malnourished children are more likely to fall ill from diarrhea2.The management of acute diarrhoea consists of the replacement of lost fluid with glucose-electrolyte oral rehydration solution. This solution, however, reduces neither the severity nor the duration of diarrhoea4 but has substantial benefit in preventing major morbidities due to dehydration and even mortality. The need of the hour is such agents which reduces both severity and duration of diarrhoea without any major impact on the motility retardation.

Probiotics are live microbial feed supplements that beneficially affect the host by improving its microbial balance. They are commonly used in the treatment and prevention of acute diarrhea. The rationale for using probiotics in acute infectious diarrhea is based on the assumption that they act against intestinal pathogens5 through a variety of physiological and mechanical hostility to pathogens.

Out of many probiotics available, Bacillus Clausii is found to be beneficial in reducing prevalence, duration and severity of diarrhea6. This study is aimed to evaluate efficacy of Bacillus Clausii in treatment of acute diarrhea in children.

 
Close